Literature DB >> 1589759

Malignant hyperthermia.

D H MacLennan1, M S Phillips.   

Abstract

In humans genetically predisposed to malignant hyperthermia, anesthesia can induce skeletal muscle rigidity, hypermetabolism, and high fever, which, if not immediately reversed, can lead to tissue damage or death. The corresponding condition in swine leads to stress-induced deaths and devalued meat products. Abnormalities in the Ca2+ release channel of skeletal muscle sarcoplasmic reticulum (the ryanodine receptor) have been implicated in the cause of both the porcine and human syndromes by physiological and biochemical studies and genetic linkage analysis. In swine, a single founder mutation in the ryanodine receptor gene (RYR1) can account for all cases of malignant hyperthermia in all breeds, but a series of different RYR1 mutations are likely to be uncovered in human families with MH. Moreover, lack of linkage between malignant hyperthermia and RYR1 in some families indicates a heterogeneous genetic basis for the human syndrome.

Entities:  

Mesh:

Substances:

Year:  1992        PMID: 1589759     DOI: 10.1126/science.1589759

Source DB:  PubMed          Journal:  Science        ISSN: 0036-8075            Impact factor:   47.728


  93 in total

1.  Excitation--contraction uncoupling by a human central core disease mutation in the ryanodine receptor.

Authors:  G Avila; J J O'Brien; R T Dirksen
Journal:  Proc Natl Acad Sci U S A       Date:  2001-03-27       Impact factor: 11.205

2.  Detection of a novel mutation in the ryanodine receptor gene in an Irish malignant hyperthermia pedigree: correlation of the IVCT response with the affected and unaffected haplotypes.

Authors:  K E Keating; L Giblin; P J Lynch; K A Quane; M Lehane; J J Heffron; T V McCarthy
Journal:  J Med Genet       Date:  1997-04       Impact factor: 6.318

3.  Effects of the 5-HT2 receptor antagonist ritanserin on halothane-induced increase of inositol phosphates in porcine malignant hyperthermia.

Authors:  A Richter; J Scholz; W Löscher; P H Tonner; F Wappler
Journal:  Naunyn Schmiedebergs Arch Pharmacol       Date:  1996-11       Impact factor: 3.000

4.  Functional properties of ryanodine receptors carrying three amino acid substitutions identified in patients affected by multi-minicore disease and central core disease, expressed in immortalized lymphocytes.

Authors:  Sylvie Ducreux; Francesco Zorzato; Ana Ferreiro; Heinz Jungbluth; Francesco Muntoni; Nicole Monnier; Clemens R Müller; Susan Treves
Journal:  Biochem J       Date:  2006-04-15       Impact factor: 3.857

Review 5.  Ryanodine receptor patents.

Authors:  Alexander Kushnir; Andrew R Marks
Journal:  Recent Pat Biotechnol       Date:  2012-12

6.  CCDI: a new ligand that modulates mammalian type 1 ryanodine receptor (RyR1).

Authors:  Chengju Tian; Chun Hong Shao; Christina Padanilam; Edward Ezell; Jaipaul Singh; Shelby Kutty; Keshore R Bidasee
Journal:  Br J Pharmacol       Date:  2014-07-02       Impact factor: 8.739

7.  Effects of dantrolene and its derivatives on Ca(2+) release from the sarcoplasmic reticulum of mouse skeletal muscle fibres.

Authors:  T Ikemoto; T Hosoya; H Aoyama; Y Kihara; M Suzuki; M Endo
Journal:  Br J Pharmacol       Date:  2001-10       Impact factor: 8.739

8.  Missense mutations in the beta-myosin heavy-chain gene cause central core disease in hypertrophic cardiomyopathy.

Authors:  L Fananapazir; M C Dalakas; F Cyran; G Cohn; N D Epstein
Journal:  Proc Natl Acad Sci U S A       Date:  1993-05-01       Impact factor: 11.205

9.  Characterization and temporal development of cores in a mouse model of malignant hyperthermia.

Authors:  Simona Boncompagni; Ann E Rossi; Massimo Micaroni; Susan L Hamilton; Robert T Dirksen; Clara Franzini-Armstrong; Feliciano Protasi
Journal:  Proc Natl Acad Sci U S A       Date:  2009-12-04       Impact factor: 11.205

Review 10.  Malignant Hyperthermia in the Post-Genomics Era: New Perspectives on an Old Concept.

Authors:  Sheila Riazi; Natalia Kraeva; Philip M Hopkins
Journal:  Anesthesiology       Date:  2018-01       Impact factor: 7.892

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.